Compare PACCAR Inc. Common Stock (PCAR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PACCAR Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? PACCAR Inc. Common Stock trades at $109.39 (market cap $56.84B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: PACCAR Inc. Common Stock is far larger — about 15.2× Tango Therapeutics Inc.'s market cap, and PACCAR Inc. Common Stock pays a 1.3% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold PACCAR Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| PCAR | TNGX | |
|---|---|---|
Market Cap | $56.84B | $3.75B |
Volume | 2,800,805 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $138.21 | $32.90 |
52-Week Low | $94.15 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $62.70B | $2.77B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PACCAR (PCAR) trades at $107.98, down 0.14% with bearish technical signals but strong fundamentals including 9% net income margin and 12.76% ROE. Recent earnings beat expectations in Q2 2026 with $1.43 EPS versus $1.36 expected. The company maintains stable cash flows with $4.3B operating cash flow projected for 2026 and recently declared a $0.35 quarterly dividend payable December 2026.
PCAR presents a mixed outlook with Wall Street consensus price target of $134.83 suggesting 25% upside potential, though technical indicators show bearish momentum. Key risks include sector sensitivity to interest rates and industrial cyclicality, while opportunities lie in the company's strong profitability metrics and defensive non-trucking segments representing over 60% of earnings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PACCAR Inc. Common Stock
PACCAR designs and manufactures heavy-duty trucks under brands including Peterbilt, Kenworth, and DAF. It also provides parts, financial services, and technology for commercial vehicles.
Read more on PCAR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
